PhysiosTEAM

29
May

BIO International Convention 2019 in Philadelphia

BIO International Convention 2019 Marie Le Grand, PhysioStim's CEO, will be present at the BIO International Convention in Philadelphia from June 3rd to June 6th, 2019. Please feel free to join us in the French Pavillon (booth ⧣2109) to discuss all your drug development projects and cardiac safety assays with Marie. See you there!! Interested in our approach? Don't hesitate to
Read more
11
Mar

New Partnership for Comprehensive In Vitro Cardiac Safety Assessment

PhysioStim & ACEA Biosciences announce partnershipA hi-tech alliance to measure preclinical cardiac safety in vitroACEA Biosciences and PhysioStim will work together to provide comprehensive in vitro cardiac safety and toxicity assessment services for pharmaceutical and biotechnology companies in Europe.Press release ACEA Biosciences Inc. (ACEA), now a part of Agilent Technologies, is a pioneer in the development and commercialization of high
Read more
11
Dec

Frédéric Delteil, PhysioStim’s new Sales Director

Introducing Frédéric DelteilPhysioStim's new Sales Director PhysioStim is pleased to announce the arrival of Frédéric Delteil, our new Sales Director. He recently joined the PhysiosTeam to animate and coordinate our sales network and increase our effectiveness in the field. Frédéric holds a Master of Science in pharmacology and pathophysiology, a Pharmacovigilance Degree and an MBA from the IAE School of
Read more
13
Feb

A new model to study chronotropic effects

PhysioStim adds new model to study chronotropic effectsTo check the cardiac safety of new drugs and compounds, PhysioStim has now added a new study model to detect potential chronotropic effects.What are chronotropic effects? Drugs and compounds with chronotropic effects change the heart rate and rhythm by affecting the electrical conduction system of the heart and the nerves that influence it.
Read more
29
Jan

2018, a new era for PhysioStim

Welcome to PhysioStim 2.0!A new era for preclinical cardiac electrophysiology Time flies by and we’ve already reached the end of January but the entire PhysioStim team would still like to take this opportunity to wish you a very happy and prosperous year 2018. We especially would like to thank our clients for their confidence over the past few years and
Read more
6
Dec

Safety pharmacology studies using human cardiomyocytes

Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) hold great potential for safety pharmacology studies. Human iPSC-derived cardiomyocytes can be used for high throughput screening, MEA, patch clamp and disease modeling applications.

21
Sep

Preclinical cardiovascular electrophysiology

Creating a European Centre of Excellence dedicated to Cardiac Safety Evaluation

14
Sep

Biopharma Outsourcing

The 3rd edition of the Biopharma Outsourcing meeting will take place in Toulouse this year. The meeting covers all aspects of service, competence and product sourcing and outsourcing for pharmaceutical and biotech companies.

14
Sep

SPS meeting 2017

The PhysioS’Team is pleased to confirm that we’ll attend the upcoming SPS meeting in Berlin.

13
Sep

cardiovascular safety studies

The company has received international recognition for its expertise in cardiac electrophysiology and preclinical safety studies. To expand its reach and complete its range of services and assays, PhysioStim is expected to team up with another CRO from across the Channel.